GlassScriptPhysician profile
Ron Palmon
NPI 1831156504
$54,362.07
in general payments reported to CMS, 2019-2025
36 companies · $5,545 in 2025
The $5,545 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,883 · 2021: $5,790 · 2022: $3,091 · 2023: $4,194 · 2024: $17K · 2025: $5,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,460 · Travel and Lodging: $904 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,796.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,460.00 |
| Travel and Lodging | $904.24 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $11,440.78 | 2024-2025 | Voquezna |
| Abbvie INC. | $8,775.99 | 2019-2025 | |
| Allergan, INC. | $8,166.27 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $7,293.57 | 2019-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,328.67 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $2,800.82 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $2,453.30 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $1,699.84 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $1,603.31 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $683.24 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $674.84 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $564.98 | 2019-2025 | Clenpiq, Rebyota |
| Ardelyx, INC. | $396.44 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $362.06 | 2022-2025 | Dupixent |
| Genzyme Corporation | $342.09 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $304.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $281.73 | 2023-2025 | |
| Lilly USA, LLC | $265.79 | 2024-2025 | Omvoh |
| Ucb, INC. | $247.47 | 2019-2020 | |
| Braintree Laboratories, INC. | $219.73 | 2019-2023 | Suflave, Sutab |
| Fujifilm Healthcare Americas Corporation | $175.34 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $165.43 | 2024-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $162.15 | 2020-2023 | |
| Shire North American Group INC | $159.03 | 2019 | |
| Exact Sciences Corporation | $139.97 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $124.97 | 2021 | |
| Amgen INC. | $120.46 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $117.91 | 2025 | Iqirvo |
| Boston Scientific Corporation | $53.67 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $51.97 | 2019-2020 | |
| Novo Nordisk INC | $49.78 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $43.84 | 2020 | |
| Fresenius Kabi USA, LLC | $30.29 | 2023 | |
| Ambu INC. | $23.92 | 2024 | |
| Evoke Pharma, INC. | $23.24 | 2025 | |
| Gilead Sciences, INC. | $14.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Palmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.